That we found significant inverse relationships between striatal DAT density and motor severity at baseline, and negative correlations between changes in 11C-PE2I BPND values and corresponding changes in motor scores, support the validity of this biomarker for tracking progression in moderate-stage PD. This evidence concerns the gene SLC6A3 and Parkinson disease.